3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
84
Breast Neoplasms
10
Neoplasm Metastasis
7
Neoplasms
5
Prostatic Neoplasms, Castration-Resistant
4
Prostate Cancer Metastatic
4
Metastatic Castration-Resistant Prostate Cancer
4
Metastatic Castration-resistant Prostate Cancer
3
Castration-resistant Prostate Cancer
3
Triple Negative Breast Neoplasms
2
Castration Resistant Metastatic Prostate Cancer
2
Adenocarcinoma of the Prostate
2
Adenocarcinoma
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Salivary Cancer
1
Recurrent Endometrial Endometrioid Adenocarcinoma
1
Prostatic Diseases
1
Prostate Carcinoma Metastatic to the Bone
1
Prostate Adenocarcinoma
1
Primary Breast Cancer ER+ve
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoadjuvant Therapy
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Progressive Castration-resistant Prostate Cancer
1
Metastatic Hormone-sensitive Prostate Cancer
1
Interventions
Doxorubicin
6
Trabectedin
5
pazopanib
4
Radiotherapy
4
ribociclib
3
pembrolizumab
3
palbociclib
3
Gemcitabine
3
brostallicin
2
Sunitinib
2
Radiation Dose Hypofractionation
2
Radiation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Immunoglobulin G
2
Imatinib Mesylate
2
Ifosfamide
2
Docetaxel
2
Dexamethasone
2
CTLA-4 Antigen
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zimberelimab
1
temsirolimus
1
tanespimycin
1
talimogene laherparepvec
1
sotigalimab
1
soblidotin
1
sitravatinib
1
saracatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Liposarcoma
×
enzalutamide
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled